한빛사
>
한빛사논문
한빛사논문
- 조회276
Adv. Healthc. Mater., Oct 03 2024, | https://doi.org/10.1002/adhm.202401868
Oligonucleotide-Linked Lipid Nanoparticles as a Versatile mRNA Nanovaccine Platform
San Hae Im 1, Youseung Chung 2, Nevena Duskunovic 1, Heewon Choi 1, Su-Hyung Park 2,3, Hyun Jung Chung 1
1Department of Biological Sciences, Korea Advanced Institute of Science and Technology, Daejeon, 34141, Republic of Korea.
2Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology, Daejeon, 34141, Republic of Korea.
3The Center for Epidemic Preparedness, Korea Advanced Institute of Science and Technology, Daejeon, 34141, Republic of Korea.
S.H.I. and Y.C. contributed equally to this work.
Corresponding Authors: Su-Hyung Park, Hyun Jung Chung
Abstract
An effective delivery platform is crucial for the development of mRNA vaccines and therapeutics. Here, a versatile platform utilizing cholesterol-modified oligonucleotides (L-oligo) that bind to the mRNA within lipid nanoparticles (LNP), and enables the effective delivery of the mRNA into target cells is introduced. mRNA incorporated into LNPs via linkage with L-oligo, termed oligonucleotide-linked LNP (lnLNP), is superior in cellular uptake and transfection efficiency in target cells in vitro and in vivo, compared to the conventional LNP formulations. It is further applied lnLNP as an mRNA vaccine platform for SARS-CoV-2, demonstrating robust induction of neutralizing activity as well as polyfunctional SARS-CoV-2-specific T-cell response in vivo. The current strategy can be versatilely applied to different LNP platforms, for vaccine and therapeutic applications against various diseases, such as infections and cancers.
논문정보
- Research article
- 2024년 10월 (BRIC 등록일 2024-10-08)
- 국내 연구진
- 바이오·의료융합 > 바이오센싱 및 나노바이오물질
댓글 작성 로그인
팝업 닫기관련 링크
연구자 키워드
소속기관 논문보기
관련분야 논문보기
